Abalos Therapeutics

Abalos Therapeutics is a novel cancer immunovirotherapy developer headquartered in Essen, Germany. It aims to advance a technology platform that leverages the unique characteristics of the lymphocytic choriomeningitis virus (LCMV), which specifically targets tumor cells. Through its proprietary Fast Evolution platform, Abalos is generating variants with optimized antitumor properties to trigger a highly precise and directed immune response, applicable to distant metastases and enabling long-term disease control.